Literature DB >> 22975207

Successful salvage therapy of refractory HIV-related cryptococcal meningitis with the combination of liposomal amphotericin B, voriconazole, and recombinant interferon-γ.

Maria N Gamaletsou1, Nikolaos V Sipsas, Dimitrios P Kontoyiannis, Aristotelis Tsiakalos, Athanasios N Kontos, Ioanna Stefanou, Theodore Kordossis.   

Abstract

We present 2 cases of HIV-related cryptococcal meningitis, persisting after 3 and 9 months, respectively, of standard treatment. Both patients were treated successfully with a salvage regimen consisting of the combination of liposomal amphotericin B (3 mg/kg), intravenous voriconazole, and subcutaneous recombinant interferon γ-1b (200 μg thrice weekly). Voriconazole was administered at an increased dose (5 mg/kg, twice daily) to overcome interactions with co-administered ritonavir. In both patients, resolution of clinical signs and symptoms, as well as sterilization of cerebrospinal fluid cultures occurred after 10 weeks of salvage therapy. No major side effects were encountered. At the end of treatment, both patients were placed on maintenance therapy with oral fluconazole; no recurrence has been observed after 4 years of follow-up.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22975207     DOI: 10.1016/j.diagmicrobio.2012.08.009

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  11 in total

1.  Cryptococcal Meningitis: Diagnosis and Management Update.

Authors:  Mahsa Abassi; David R Boulware; Joshua Rhein
Journal:  Curr Trop Med Rep       Date:  2015-06-01

2.  An estimate of the burden of serious fungal diseases in Greece.

Authors:  M N Gamaletsou; M Drogari-Apiranthitou; D W Denning; N V Sipsas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-04-16       Impact factor: 3.267

Review 3.  Microbial recognition and danger signals in sepsis and trauma.

Authors:  Steven L Raymond; David C Holden; Juan C Mira; Julie A Stortz; Tyler J Loftus; Alicia M Mohr; Lyle L Moldawer; Frederick A Moore; Shawn D Larson; Philip A Efron
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-01-20       Impact factor: 5.187

Review 4.  Recent advances in AIDS-related cryptococcal meningitis treatment with an emphasis on resource limited settings.

Authors:  Sarah Lofgren; Mahsa Abassi; Joshua Rhein; David R Boulware
Journal:  Expert Rev Anti Infect Ther       Date:  2017-02-09       Impact factor: 5.091

Review 5.  The Significance of Interferon-γ in HIV-1 Pathogenesis, Therapy, and Prophylaxis.

Authors:  Shannon R Roff; Ezra N Noon-Song; Janet K Yamamoto
Journal:  Front Immunol       Date:  2014-01-13       Impact factor: 7.561

Review 6.  Integrated therapy for HIV and cryptococcosis.

Authors:  Sirawat Srichatrapimuk; Somnuek Sungkanuparph
Journal:  AIDS Res Ther       Date:  2016-11-29       Impact factor: 2.250

Review 7.  Therapy of Mucormycosis.

Authors:  Nikolaos V Sipsas; Maria N Gamaletsou; Amalia Anastasopoulou; Dimitrios P Kontoyiannis
Journal:  J Fungi (Basel)       Date:  2018-07-31

Review 8.  Diagnosis and Management of Central Nervous System Cryptococcal Infections in HIV-Infected Adults.

Authors:  Caleb Skipper; Mahsa Abassi; David R Boulware
Journal:  J Fungi (Basel)       Date:  2019-07-19

9.  The clinical profiles and outcomes of HIV-negative cryptococcal meningitis patients in type II diabetes mellitus.

Authors:  Hang Li; Xiaojing Li; Lei Zhang; Wenjie Fang; Keming Zhang; Amir Arastehfar; Macit Ilkit; Dongying Hu; Xianzhen Chen; Huiwei Wang; Liyan Ling; Jianjun Lin; Bin Xu; Wanqing Liao; Weihua Pan; Qilong Zhang
Journal:  BMC Infect Dis       Date:  2021-02-27       Impact factor: 3.090

Review 10.  Mucormycosis Amid COVID-19 Crisis: Pathogenesis, Diagnosis, and Novel Treatment Strategies to Combat the Spread.

Authors:  Shreya Dogra; Akanksha Arora; Aashni Aggarwal; Gautam Passi; Akanksha Sharma; Gurpal Singh; Ravi P Barnwal
Journal:  Front Microbiol       Date:  2022-01-04       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.